Last reviewed · How we verify
Dexamethosone
Dexamethosone is a Small molecule drug developed by National Institute of Nursing Research (NINR). It is currently in Phase 3 development. Also known as: Mestinon.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dexamethosone |
|---|---|
| Also known as | Mestinon |
| Sponsor | National Institute of Nursing Research (NINR) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Dexmedetomidine and Dexamethasone Added as Adjuvant Infraclavicular Brachial Plexus Block in Upper Limb Surgery
- A Prospective Controlled Treatment Trial for Post-Traumatic Headaches (PHASE3)
- ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy (NA)
- Dextenza With ILUX for Treatment of MGD (PHASE4)
- Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma (PHASE2)
- Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications (NA)
- A Phase II Study of Nasal NK/T-cell Lymphoma (PHASE2)
- Sleep, Fatigue, and Dexamethosone in Children With Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethosone CI brief — competitive landscape report
- Dexamethosone updates RSS · CI watch RSS
- National Institute of Nursing Research (NINR) portfolio CI
Frequently asked questions about Dexamethosone
What is Dexamethosone?
Who makes Dexamethosone?
Is Dexamethosone also known as anything else?
What development phase is Dexamethosone in?
Related
- Manufacturer: National Institute of Nursing Research (NINR) — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Mestinon
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing